Antibiotic resistance: India’s silent pandemic

 INTRODUCTION:

Antibiotics transformed medicine, but in India their power is fading fast. The Indian Council of Medical Research (ICMR) estimates that drug‑resistant infections already kill one in every six hospitalised patients with sepsis, and the trend is worsening. Surveillance data from 50 medical‑college labs in 27 States show that Klebsiella pneumoniae and Acinetobacter baumannii now resist last‑line carbapenems at rates above 40 percent, while Escherichia coli tops 65 percent resistance to fluoroquinolones.

Recent peer‑reviewed studies echo the alarm. A two‑year analysis of 8,359 specimens in a South‑Indian tertiary centre (July 2022‑July 2024) found carbapenem resistance in 48 % of A. baumannii and 38.6 % of K. pneumoniae isolates, with three different carbapenemase genes often co‑existing in the same strain. Meanwhile, CSIR‑NEERI scientists sampling the glacier‑fed upper Ganga this year discovered naturally occurring bacteriophages that lyse the notorious ESKAPEE(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp,) superbugs—a promising lead for future phage therapy. On the drug‑development front, India’s start‑up Bugworks has advanced the novel macrolide nafithromycin into Phase III trials with support from the Biotechnology Industry Research Assistance Council (BIRAC), the first truly new Indian antibiotic class in three decades.

REASONS BEHIND ANTIBIOTIC RESISTANCE DEVELOPMENT:

1. Overuse of Antibiotics: Overuse creates selective pressure, allowing only resistant bacteria to survive and multiply. Antibiotics are often prescribed unnecessarily, such as for viral infections like the common cold or flu. India has one of the highest antibiotic consumption rates in the world, often without proper prescriptions.

2. Incomplete or Incorrect Use: People sometimes stop antibiotics early once they feel better, instead of completing the full course. This allows some bacteria to survive and potentially develop resistance. Taking lower-than-prescribed doses or using leftover antibiotics can also encourage resistance.

3. Widespread Use in Agriculture: These drugs can enter the food chain or water systems, exposing bacteria in animals and the environment to antibiotics—leading to cross-species resistance. In India and globally, antibiotics are used in livestock and poultry for growth promotion and disease prevention.

4. Poor Infection Control in Healthcare Settings: Multi-drug resistant organisms (like Klebsiella pneumoniae and Acinetobacter baumannii) thrive in these settings. In hospitals, improper sanitation, overcrowding, and lack of infection control measures lead to the spread of resistant bacteria.

5. Environmental Contamination: In India, studies have found high concentrations of antibiotics in rivers, promoting environmental selection of resistant microbes. Pharmaceutical waste and hospital sewage often contain antibiotic residues.

6. Lack of Regulation and Monitoring: Poor enforcement of existing laws allows irrational drug combinations and counterfeit antibiotics to circulate. Until recently, India had weak control over antibiotic sales—many could be purchased without prescriptions.

7. Horizontal Gene Transfer: Once resistance emerges in one population, it can spread rapidly. Bacteria can share resistance genes with one another—even across species—through mechanisms like plasmid exchange.

In summary, antibiotic resistance occurs because of misuse, overuse, environmental exposure, and bacterial evolution. It is accelerated by weak regulations, poor sanitation, and a lack of awareness. To combat this, we need rational antibiotic use, better hygiene, agricultural reform, and strict regulation.

STEPS TAKEN BY GOI TO ADDRESS THE PROBLEM:

Policy moves gaining pace

National framework. India adopted a National Action Plan on AMR (NAP‑AMR) in 2017. Under NAP the National Antimicrobial Resistance Surveillance Network (NARS‑Net) expanded to 50 sentinel sites and a dedicated National Reference Laboratory at NCDC.

Tighter regulation. In August 2024 the Drug Controller General banned 156 irrational fixed‑dose combination (FDC) antibiotics; Schedule H1 already compels pharmacists to retain prescriptions for last‑line drugs. Kerala went further: Operation AMRITH (January 2024) makes over‑the‑counter sale of all antibiotics illegal, backed by surprise audits and a public whistle‑blowing portal.

State action plans. Seven states—including Telangana (October 2024) and Karnataka—have drafted their own AMR roadmaps, adopting “One‑Health” coordination across human, animal and environmental sectors.

Hospital stewardship. NCDC’s infection‑prevention guidelines are now mandatory for the 50 networked tertiary hospitals; electronic audits of prescriptions and rapid diagnostic tests are being rolled out to curb empirical broad‑spectrum use.

Public engagement. The Red‑Line campaign marks cartons of prescription‑only antibiotics; World AMR Awareness Week each November drives community events. India also addressed the 2024 UN General Assembly high‑level meeting on AMR, calling for global financing of new antibiotics and diagnostics.

WHY THE STAKES ARE UNIQUELY HIGH?

India’s heavy burden of infectious disease, high antibiotic consumption (roughly 10 billion doses in 2024), crowded hospitals, and porous regulation give resistant bacteria fertile ground. Economists project that by 2030 AMR could shave 1.5 % off national GDP and push 2.2 million Indians into extreme poverty through prolonged illness and out‑of‑pocket spending. Early evidence suggests stewardship works: hospitals that implemented NCDC protocols saw a 17 % fall in carbapenem use within twelve months, with no rise in mortality.

What next?

Scale proven state models. Nationwide adoption of Kerala’s prescription‑only enforcement and “unused‑drug return” (PROUD) bins could cut community misuse.

Invest in local drugs and phages. Incentivise translational research—Ganga phage libraries, AI‑guided molecule design, and venture‑capital tax credits—to diversify the pipeline.

Fix the sewage link. AMR genes flow from hospitals to rivers; upcoming AMRUT 2.0 funds for wastewater treatment must include routine monitoring of resistance genes.

Empower every prescriber. Embed point‑of‑care diagnostics and e‑stewardship prompts in Ayushman Bharat digital health records.

CONCLUSION:

Antibiotic resistance is often called a “slow tsunami”; in India the waves are already lapping at our hospital doors. Comprehensive surveillance, responsible prescribing, robust regulation and bold R&D can still turn the tide—if we act together, and fast.